- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03851965
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) (SPARSE)
A Prospective Observational Study on Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Adult Patients Undergoing Major Non-cardiac Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND
Soluble urokinase plasminogen activator receptor
The biomarker soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the cell membrane-bound protein urokinase plasminogen activator receptor (uPAR), which is expressed mainly on immune cells, endothelial cells, and smooth muscle cells. uPAR is released during inflammation or immune activation, and therefore the suPAR level reflects the extent of immune activation in the individual. All human beings have a baseline level of suPAR that is individually determined and increases with age. Studies have shown that the suPAR level is associated with morbidity and mortality in a number of acute and chronic diseases and in the general population. The suPAR level is elevated across diseases, and not solely associated with one specific disease. Therefore, suPAR is applicable as a prognostic marker and not as a diagnostic marker. This characteristic may be utilized for risk stratification in unselected patients.
In critically ill patients, the suPAR level is significantly increased. suPAR is an independent prognostic marker, and the change over time correlates with organ dysfunction. suPAR is elevated and has a prognostic value in patients with: SIRS (systemic inflammatory response syndrome), sepsis/septic shock, burn injuries, and traumatic brain injuries. The suPAR level reflects the body's immune response to infections, and the level increases with the severity of the infection. In patients with organ dysfunction, the suPAR value is often a two-digit value. In particular hepatic and renal dysfunction affects the suPAR level.
suPAR in surgery
The suPAR level is elevated in patients with infections, chronic diseases, and cancer compared to healthy individuals. A high suPAR level is associated with increased mortality risk, poor prognosis, postoperative pneumonia, and prosthetic joint infection. suPAR is a well-studied biomarker predicting prognosis, disease severity, and organ dysfunction and is being considered as a marker of the individual's inflammatory status. It has been demonstrated that biomarkers are able to improve triage and are effective in identifying high and low risk patients among acutely admitted patients. Improving the preoperative risk stratification using biomarkers may optimize the patient's clinical outcome.
AIM
SPARSE is a single-center observational study aiming to investigate if suPAR measured preoperatively and immediately after surgery can predict the risk of future complications and post-operative mortality in adults following major non-cardiac surgery.
METHODS
Design
This is a prospective observational study designed in accordance with the declaration of Helsinki. The study will be register at Clinical Trials.gov and will be approved by the Institutional Review Board of the University Hospital of Larisa, under reference number.
Management of Anesthesia and Surgical Procedures
Endotracheal intubation and anesthetic care will be performed according to institutional routine. Intravenous induction of general anaesthesia will include midazolam 0.15-0.35 mg/kg iv over 20-30 seconds, fentanyl 1μg/kg, propofol 1.5-2 mg/kg, ketamine 0.2 mg/kg (intravenous bolus), and rocurnium 0.6 mg/kg. All drugs will be prepared in labelled syringes and induction will be achieved by administration of a predetermined iv bolus dose on the basis of the patient's weight and/or age. Laryngoscopy and intubation will proceed in a standard fashion, while the position of the endotracheal tube will be confirmed by auscultation and capnography/capnometry. The patients will then connected to an automated ventilator (Draeger Primus®; Drägerwerk AG & Co., Lübeck, Germany).
All patients will be ventilated using a lung-protective strategy with tidal volume of 7 mL/kg, positive end-expiratory pressure of 6-8 cmH2O, plateau pressures <30 cmH2O, and recruitment maneuvers repeated every 30 min after tracheal intubation. Maintenance of general anesthesia will include desflurane 1.0 MAC with 40% oxygen and 60% air, while intraoperative dose changes will be left to the anesthesiologist in charge of the patient. Depth of anesthesia (bispectral index-BIS, Covidien, France) will be monitored, with the target ranging between 40 and 60. Normocapnia will be maintained by adjusting the respiratory rate as needed, while normothermia (37ºC) will be maintained throughout the intraoperative period.
Sampling and laboratory measurements
Participants will undergo sampling of peripheral venous blood, immediately after arrival to the OR, and at the Post-Anesthesia Care Unit (PACU). Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until suPAR levels are determined.
Microcirculation flow analysis
In addition to routine hemodynamic data, sublingual microvascular flow will be measured using noninvasive technology. Measurements will be obtained preoperatively (PRE), intraoperatively (INT), and postoperatively after arrival in the PACU (POST). At each time point, the microcirculatory network of the sublingual mucosa will be imaged using sidestream darkfield (SDF+) videomicroscopy which has an increased optical resolution resulting in one pixel recording an area of 0.56 μm2.
Data Collection and Monitoring
Data analysis will be based on predefined data points on a prospective data collection form. The staff will be blinded to measurements until the end of the study and all data are analyzed. Clinical monitoring throughout the study will be performed to maximize protocol adherence, while an independent Data and Safety Monitoring research staff will monitor safety, ethical, and scientific aspects of the study. Data collection will include demographics, anesthesia parameters, C-reactive protein, P-POSSUM score, ACS-NSQIP score, APACHE II, SOFA, and the Charlson Age-Comorbidity Index (Charlson score). A SAS macro based on ICD-10 diagnoses will be used to calculate the Charlson score. Two other simpler models adding predictive value to the ASA classification will be also used; the Surgical Mortality Probability Model and a similar model proposed by Glance and Donati.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Thessaly
-
Larisa, Thessaly, Greece, 41110
- University Hospital of Larisa, Department of Anesthesiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All operative approaches
- Age ≥ 18 years
- American Society of Anesthesiologists' (ASA) physical status I to IV
Exclusion Criteria:
- Age <18 years
- Any infection within the previous 4 weeks
- Severe liver disease
- Renal replacement therapy pre-operatively
- Previously received transplant
- Allergies
- Inflammatory disorders
- Immune system disorders
- Connective tissue disease
- Administration of opioids during the past week
- Asthma
- Obesity (BMI ≥ 30 kg m-2)
- Mental disability
- Severe psychiatric disease
- Alcohol or other abuse,
- Legal incapacity or limited legal capacity
- Subjects within the exclusion period of another study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with postoperative complications
Time Frame: Within the first 90 postoperative days
|
Number of participants with postoperative complications
|
Within the first 90 postoperative days
|
Number of participants admitted to Intensive Care Unit
Time Frame: Within the first 60 postoperative days
|
Number of participants admitted to Intensive Care Unit
|
Within the first 60 postoperative days
|
Number of deaths
Time Frame: Within the first 60 postoperative days
|
Number of deaths
|
Within the first 60 postoperative days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with intraoperative complications
Time Frame: During surgery
|
Number of participants with desaturation [SpO2 <92% for 3 minutes or more], need for unplanned recruitment maneuvers, hypotension [defined as systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg for 3 minutes or more or need of vasoactive drugs for correction]
|
During surgery
|
Number of participants with need for unplanned vasoactive drugs during surgery
Time Frame: During surgery
|
Number of participants with need for vasoactive drugs not planned before and/or continuous infusion during surgery
|
During surgery
|
Number of participants with acute new arrhythmia during sugery
Time Frame: During surgery
|
Number of participants with atrial fibrillation, sustained ventricular tachycardia, supraventricular tachycardia, and/or cardiac arrest during surgery
|
During surgery
|
Number of reintubations
Time Frame: At 30 days
|
Number of participants being reintubated after extubation
|
At 30 days
|
Survival
Time Frame: At 30 days, at 90 days, and at 1 year
|
Survival
|
At 30 days, at 90 days, and at 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Athanasios Chalkias, MD, PhD, University of Thessaly, Faculty of Medicine
Publications and helpful links
General Publications
- Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999 May 19;91(10):869-74. doi: 10.1093/jnci/91.10.869.
- Svendsen MN, Ytting H, Brunner N, Nielsen HJ, Christensen IJ. Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer. Surg Infect (Larchmt). 2006 Oct;7(5):463-71. doi: 10.1089/sur.2006.7.463.
- Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Moller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jorgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28.
- Chalkias A, Laou E, Kolonia K, Ragias D, Angelopoulou Z, Mitsiouli E, Kallemose T, Smith-Hansen L, Eugen-Olsen J, Arnaoutoglou E. Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE). Surgery. 2022 Jun;171(6):1619-1625. doi: 10.1016/j.surg.2021.10.012. Epub 2021 Nov 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTHDA-AC01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgery--Complications
-
Duke UniversityWithdrawnSurgical Complications From Surgery | Surgical Complications From Bladder Surgery | Surgical Complications From Bowel Surgery
-
Poudre Valley Health SystemTerminatedSurgery | Surgery--ComplicationsUnited States
-
University of KwaZuluMedical Research Council, South AfricaCompletedMortality | Surgery | Surgery- ComplicationsSouth Africa, Algeria, Benin, Burundi, Cameroon, Congo, The Democratic Republic of the, Congo, Egypt, Ethiopia, Gambia, Ghana, Kenya, Libyan Arab Jamahiriya, Madagascar, Mali, Mauritius, Namibia, Nigeria, Niger, Senegal, Tanzania, Tog... and more
-
Baylor Research InstituteChiesi USA, Inc.RecruitingSurgery | Cardiac Surgery | Surgery--Complications | Percutaneous Coronary InterventionUnited States
-
Western University, CanadaNot yet recruitingSurgery | Surgery--Complications | Pulmonary Complication
-
Faiza GabaQueen Mary University of London; University of Hertfordshire; University of Aberdeen and other collaboratorsRecruitingGynecologic Cancer | Surgery | Surgery--ComplicationsUnited Kingdom
-
Hacettepe UniversityCompletedSurgery--Complications | Newborn Morbidity | Neonatal SurgeryTurkey
-
Washington University School of MedicineNational Institute of Nursing Research (NINR)CompletedSurgery | Surgery--Complications | Perioperative/Postoperative ComplicationsUnited States
-
Hospices Civils de LyonRecruitingPost-operative Complications After Colorectal Surgery | Post-operative Complications After Gastric Surgery | Post-operative Complications After Bariatric SurgeryFrance
-
Henan Cancer HospitalThe First Affiliated Hospital of Zhengzhou University; Henan Provincial People... and other collaboratorsRecruitingSurgery--ComplicationsChina
Clinical Trials on Soluble Urokinase Plasminogen Activator Receptor
-
Larissa University HospitalRecruiting
-
Poitiers University HospitalCompletedMortality | Abdominal Pain | Emergency Department | Soluble Urokinase Plasminogen Activation ReceptorFrance
-
Second Affiliated Hospital of Nanchang UniversityChanghai HospitalRecruitingAneurysmal Subarachnoid HemorrhageChina
-
Grifols Therapeutics LLCCompletedAcute Peripheral Arterial OcclusionUnited States, Peru, Belgium, Bulgaria, Czech Republic, Germany, India, Poland, Romania, Serbia, Slovakia, Spain
-
Cengiz Gokcek Women's and Children's HospitalUnknownPreterm Premature Rupture of MembranesTurkey
-
General Hospital of Shenyang Military RegionWithdrawn
-
The First Affiliated Hospital of Zhengzhou UniversityTechpool Bio-Pharma Co., Ltd.Recruiting
-
General Hospital of Shenyang Military RegionCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedPleural Diseases | Pleural Effusion | Empyema, PleuralSpain